Form 4: Eli Lilly Executive Hernandez Reports Stock Transactions

Executive Vice President Edgardo Hernandez of Eli Lilly & Co. reported the acquisition and disposal of company stock and restricted stock units on November 1, 2024.

Summary

• Edgardo Hernandez, an Executive Vice President at Eli Lilly & Co., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On November 1, 2024, Hernandez acquired 1,687 shares of common stock through the vesting of restricted stock units.
• Also on November 1, 2024, he disposed of 750.799 shares of common stock at a price of $818.93 per share.
• Following these transactions, Hernandez directly owns 30,618.201 shares of common stock and indirectly owns 865.22 shares through a 401(k) plan.
• He also holds 0 restricted stock units after the vesting of 1,687 units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of stock transactions by an executive, and does not indicate any positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and Eli Lilly's filing is consistent with these requirements.
• Other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) also have executives who regularly file Form 4s when they trade company stock.
• The transactions reported are typical for executives who receive stock-based compensation.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of routine executive compensation and do not indicate any significant change in the company's financial health or outlook.

Key Dates

Keywords

Form 4, Eli Lilly, stock transaction, beneficial ownership, restricted stock units, executive compensation, insider trading